CN112423774A - 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法 - Google Patents

用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法 Download PDF

Info

Publication number
CN112423774A
CN112423774A CN201980047677.1A CN201980047677A CN112423774A CN 112423774 A CN112423774 A CN 112423774A CN 201980047677 A CN201980047677 A CN 201980047677A CN 112423774 A CN112423774 A CN 112423774A
Authority
CN
China
Prior art keywords
disease
cpg
circulating
dementia
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980047677.1A
Other languages
English (en)
Chinese (zh)
Inventor
L·H·L·特兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN112423774A publication Critical patent/CN112423774A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980047677.1A 2018-05-15 2019-05-15 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法 Pending CN112423774A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862671466P 2018-05-15 2018-05-15
US201862671485P 2018-05-15 2018-05-15
US62/671,466 2018-05-15
US62/671,485 2018-05-15
US201862674855P 2018-05-22 2018-05-22
US62/674,855 2018-05-22
PCT/US2019/032403 WO2019222339A1 (en) 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Publications (1)

Publication Number Publication Date
CN112423774A true CN112423774A (zh) 2021-02-26

Family

ID=68541027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980047677.1A Pending CN112423774A (zh) 2018-05-15 2019-05-15 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法

Country Status (9)

Country Link
US (3) US11090303B2 (enExample)
EP (1) EP3843768A4 (enExample)
JP (2) JP7699378B2 (enExample)
CN (1) CN112423774A (enExample)
AU (1) AU2019271189A1 (enExample)
BR (1) BR112020023252A2 (enExample)
GB (1) GB202015788D0 (enExample)
MA (1) MA53500A (enExample)
WO (1) WO2019222339A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114582507A (zh) * 2022-03-04 2022-06-03 青海省畜牧兽医科学院 基于地理探测器的泡型包虫病环境风险因子分析方法
CN119770491A (zh) * 2024-12-20 2025-04-08 北京大学 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53500A (fr) 2018-05-15 2021-08-18 Lloyd Hung Loi Tran Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques
US20240398792A1 (en) * 2018-05-15 2024-12-05 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
CA3179317A1 (en) 2020-04-20 2021-10-28 Lloyd Hung Loi TRAN Methods for the prophylaxis and treatment of covid and covid-19
WO2022051631A1 (en) 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
IL305132A (en) * 2021-02-12 2023-10-01 Neuren Pharmaceuticals Ltd Preparations for the treatment of the Prader-Willi phenomenon
KR20260049797A (ko) * 2023-07-12 2026-04-14 로이드 트란 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis
WO2025160184A1 (en) * 2024-01-23 2025-07-31 Lloyd Tran Methods for the prophylaxis and treatment of obesity and related conditions and disorders
WO2025179250A1 (en) * 2024-02-25 2025-08-28 Lloyd Tran Methods for the prophylaxis and treatment of autism related disorders
WO2025198995A1 (en) * 2024-03-18 2025-09-25 Lloyd Tran Methods for the prophylaxis and treatment of stroke related disorders
WO2026112551A1 (en) * 2024-11-24 2026-05-28 Lloyd Tran Methods for the prophylaxis and treatment of substance use disorder (sud) including but not limited to alcohol use disorder (aud)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US20030109531A1 (en) * 2001-11-13 2003-06-12 Tran Loi H Therapeutic agent composition and method of use
US20060258663A1 (en) * 2003-09-03 2006-11-16 Neuren Pharmaceuticals Limited Cyclic G-2AllylProline in treatment of Parkinson's disease
CN101466366A (zh) * 2006-06-15 2009-06-24 纽朗制药公司 用于治疗认知障碍的α-氨基酰胺衍生物
US20090232775A1 (en) * 2002-11-20 2009-09-17 Goran Bertilsson Compounds and methods for increasing neurogenesis
US20110201614A1 (en) * 2003-09-03 2011-08-18 Michael John Bickerdike Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US20150306171A1 (en) * 2001-11-13 2015-10-29 Lloyd Hung Loi Tran Therapeutic agent composition and method of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2670563B2 (ja) 1988-10-12 1997-10-29 富士通株式会社 半導体装置の製造方法
JP2757960B2 (ja) 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
ES2101865T3 (es) 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
CA2178711A1 (en) 1993-12-23 1995-06-29 Peter David Gluckman Composition and methods to improve neural outcome
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5942422A (en) 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
IL138342A0 (en) 1998-03-17 2001-10-31 Pfizer Prod Inc Bicyclo[2.2.1] heptanes and related compounds
US6258582B1 (en) 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
KR20020079731A (ko) 1999-11-05 2002-10-19 액소닉스, 인코포레이티드. 아밀로이드, 아밀로이드-유사 침착물, 또는 β-쉬이트가풍부한 그의 병리학적 전구체로의 비정상적 단백질 폴딩과관련된 질환의 치료에 있어서 생체내에서 사용하기에적합한 펩티드 동족체 및 유사체
US6689904B2 (en) 2001-06-29 2004-02-10 Wyeth Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
SI3024463T1 (sl) * 2013-07-25 2020-08-31 Neuren Pharmaceuticals Limited Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj
EP3551354B1 (en) * 2018-02-19 2021-09-08 The Material Works, Ltd. Width and speed control for sheet metal descaler and methods of using same
MA53500A (fr) 2018-05-15 2021-08-18 Lloyd Hung Loi Tran Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US20030109531A1 (en) * 2001-11-13 2003-06-12 Tran Loi H Therapeutic agent composition and method of use
US20150306171A1 (en) * 2001-11-13 2015-10-29 Lloyd Hung Loi Tran Therapeutic agent composition and method of use
US20090232775A1 (en) * 2002-11-20 2009-09-17 Goran Bertilsson Compounds and methods for increasing neurogenesis
US20060258663A1 (en) * 2003-09-03 2006-11-16 Neuren Pharmaceuticals Limited Cyclic G-2AllylProline in treatment of Parkinson's disease
US20110201614A1 (en) * 2003-09-03 2011-08-18 Michael John Bickerdike Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
CN101466366A (zh) * 2006-06-15 2009-06-24 纽朗制药公司 用于治疗认知障碍的α-氨基酰胺衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114582507A (zh) * 2022-03-04 2022-06-03 青海省畜牧兽医科学院 基于地理探测器的泡型包虫病环境风险因子分析方法
CN119770491A (zh) * 2024-12-20 2025-04-08 北京大学 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用

Also Published As

Publication number Publication date
EP3843768A1 (en) 2021-07-07
WO2019222339A1 (en) 2019-11-21
JP2025084741A (ja) 2025-06-03
US20230381175A1 (en) 2023-11-30
US11090303B2 (en) 2021-08-17
JP7699378B2 (ja) 2025-06-27
US20200054629A1 (en) 2020-02-20
BR112020023252A2 (pt) 2021-02-23
MA53500A (fr) 2021-08-18
GB202015788D0 (en) 2020-11-18
EP3843768A4 (en) 2022-11-23
AU2019271189A1 (en) 2021-01-07
US20220000866A1 (en) 2022-01-06
JP2021524864A (ja) 2021-09-16
US12070458B2 (en) 2024-08-27

Similar Documents

Publication Publication Date Title
US12070458B2 (en) Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
TW201134482A (en) Aptamers to β -NGF and their use in treating β -NGF mediated diseases and disorders
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
CN107266332A (zh) Ssao的取代的3‑卤代烯丙基胺抑制剂及其用途
TW201038544A (en) Anti-neurodegenerative diseases agents
EA025780B1 (ru) Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
CN116390723A (zh) 用于将生物素递送至线粒体的方法和组合物
JP2016539188A (ja) 新規カベオリンモジュレーターを使用する自己免疫および／または炎症疾患の治療
CN102625707A (zh) Hip/pap或其衍生物的新应用
JP2022552217A (ja) 脊髄損傷の治療のため及び／又は髄鞘再形成のためのペプチドの全身投与
JP2024541507A (ja) 外傷性脳損傷を治療するためのａｌｐｈａ－１０６２
Yin et al. TGF-β/RhoA/ROCK signaling activation orchestrates ciliary body EMT and fibrosis in myopia
JP2021527127A (ja) 中枢神経系内のグルコースレベルを増強する方法
CN102813914B (zh) 一种用于治疗或预防脑血管及相关疾病的药物组合物
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
US20240374691A1 (en) Glp-1r agonists for use in a treatment of neurologial impairment associated with viral infection
CN121443298A (zh) 用于治疗持续性脑震荡后症状的苯加兰他敏
CN101658522A (zh) 他克林短链二聚体在制备治疗神经退行性疾病药物中的应用
WO2023068176A1 (ja) 神経細胞増殖促進剤及びその使用
CN121816183A (zh) 治疗轻度认知障碍的治疗剂组合物以及联合疗法的应用方法
RU2744453C2 (ru) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
Yanamadala Peptide carriers to improve uptake and functionality and to cross BBB to arrest secondary injury post TBI
RU2362554C2 (ru) Регенерирующее противовоспалительное средство и способы лечения с помощью этого средства
WO2025179250A1 (en) Methods for the prophylaxis and treatment of autism related disorders
WO2009149621A1 (zh) 淫羊藿次苷在制备用于预防或治疗男性或女性性功能障碍的产品中用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination